US Stocks, page 37 of 41 — 24 articles published 2026-06-17 ~ 2026-06-18.
SWKS (Skyworks Solutions) stock outlook 2026: in-depth analysis of RF semiconductor leadership, Apple concentration risk, broad-markets diversification, free cash flow, dividend, and competition with QRVO and AVGO. US investor perspective.
D.R. Horton (DHI) stock outlook 2026: entry-level housing strategy, mortgage buydown mechanics, Forestar land model, margin-volume tradeoff, and how DHI stacks up against LEN, PHM, and NVR. US investor perspective on rate-cycle leverage.
Expedia Group (EXPE) stock outlook 2026 — deep analysis of One Key loyalty integration, Vrbo vs ABNB vacation rental battle, B2B white-label platform, Google disintermediation threat, and bull/base/bear scenarios for US investors.
A deep-dive into PTON Peloton stock outlook for 2026 — subscription pivot, cost restructuring, subscriber churn dynamics, leadership strategy, competitive threats from Apple Fitness+ and Lululemon Studio, and an honest assessment of turnaround credibility for US investors.
MOS (Mosaic Company) stock outlook for 2026: potash and phosphate cycle positioning, Mosaic Fertilizantes Brazil strategy, global supply dynamics post-Belarus/Russia disruptions, capital discipline, and a three-scenario analysis for investors.
A deep-dive into Ecolab (ECL) for long-term investors: razor-and-blade economics, water scarcity tailwinds, data-center cooling demand, Dividend Aristocrat status, competitive moat, and a three-scenario analysis for 2026 and beyond.
NCLH stock analysis for 2026: Norwegian Cruise Line Holdings balances surging cruise demand and premium brand strength against a heavy debt load. Deep-dive into the bull/bear case, fleet expansion, competitive positioning vs RCL and CCL, and investor checklist.
Deep-dive on ROKU stock for 2026: platform revenue model, The Roku Channel, OS market share, competition from Amazon Fire TV and Google TV, ad cyclicality, international expansion, and the path to GAAP profitability. Independent analyst take.
A deep-dive structural analysis of Elastic N.V. (ESTC) for 2026, examining its Search AI, vector search, and RAG positioning across three business pillars — Search, Observability, and Security — against competitors like Datadog, Splunk, and AWS OpenSearch.
Cincinnati Financial (CINF) is one of America's longest-running Dividend Kings, but its equity-heavy investment portfolio and independent agency model create a risk/reward profile unlike any other P&C insurer. Here's the honest 2026 investment case.
DocuSign's 2026 stock outlook: whether the Intelligent Agreement Management (IAM) platform pivot can unlock new growth beyond a commoditizing e-signature core, with bull, base, and bear scenarios.
EXAS Exact Sciences 2026 stock outlook: Cologuard Plus launch, Oncotype DX momentum, MCED pipeline, and the path to profitability amid rising competition from Guardant Shield and Grail's Galleri test.
Globe Life (GL) stock forecast 2026: in-depth analysis of Globe Life's middle-income life and supplemental health insurance business model, distribution channels, regulatory risks, competitive position against MetLife and Aflac, and bull/base/bear scenarios for investors.
INCY Incyte stock forecast 2026: Jakafi ruxolitinib patent cliff, Opzelura atopic dermatitis vitiligo growth, JAK inhibitor competition from BMS and Pfizer, pipeline catalysts, and what biopharma investors must verify before buying.
Mettler-Toledo (MTD) stock outlook 2026: precision instruments, pricing power, China exposure, and bull/base/bear scenarios. Qualitative structural analysis for investors.
NBIX Neurocrine Biosciences 2026 stock forecast: deep-dive into Ingrezza's tardive dyskinesia franchise durability, the Crenessity CAH launch, and whether this CNS biopharma can sustain its valuation as it transitions from one-product dependency to a multi-asset platform.
UiPath (PATH) 2026 stock outlook: how the RPA leader is pivoting to agentic automation, where the bull and bear cases diverge, and what enterprise software investors need to watch this year.
Insulet (PODD) stock analysis for 2026: Omnipod 5 AID momentum, type-2 diabetes expansion, pharmacy-channel growth, GLP-1 overhang debate, and competitive risks from Tandem and Medtronic.
STERIS plc 2026 outlook: infection prevention, AST contract sterilization, life sciences — bull/base/bear scenarios, risks, and what to watch.
Waters Corporation (WAT) stock outlook 2026: deep dive into its LC/MS consumables recurring revenue engine, GLP-1 manufacturing QC tailwinds, China demand risks, and competitive positioning against Agilent, Thermo Fisher, and Danaher.
WTW Willis Towers Watson stock forecast 2026: deep dive into insurance broker margin expansion, buyback story, Risk & Broking vs HWC segments, and competitive gap vs MMC and Aon.
An expert look at Brown & Brown (BRO) stock for 2026 — decentralized culture, M&A roll-up engine, Programs segment moat, and the real risks that could slow the compounder.
SentinelOne (S stock) 2026 forecast: how the AI-native Singularity platform stacks up against CrowdStrike, Microsoft, and PANW — plus the real bull and bear cases every investor needs to weigh.
Twilio (TWLO) has shifted from growth-at-all-costs to FCF discipline and AI-driven engagement. This deep-dive covers CPaaS moat, Segment CDP, ContextSuite, and bull/bear scenarios for 2026.